345 related articles for article (PubMed ID: 31170384)
1. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.
Raymond E; Chong E; Winikoff B; Platais I; Mary M; Lotarevich T; Castillo PW; Kaneshiro B; Tschann M; Fontanilla T; Baldwin M; Schnyer A; Coplon L; Mathieu N; Bednarek P; Keady M; Priegue E
Contraception; 2019 Sep; 100(3):173-177. PubMed ID: 31170384
[TBL] [Abstract][Full Text] [Related]
2. Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.
Chong E; Shochet T; Raymond E; Platais I; Anger HA; Raidoo S; Soon R; Grant MS; Haskell S; Tocce K; Baldwin MK; Boraas CM; Bednarek PH; Banks J; Coplon L; Thompson F; Priegue E; Winikoff B
Contraception; 2021 Jul; 104(1):43-48. PubMed ID: 33781762
[TBL] [Abstract][Full Text] [Related]
3. A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S.
Chong E; Frye LJ; Castle J; Dean G; Kuehl L; Winikoff B
Contraception; 2015 Sep; 92(3):215-9. PubMed ID: 26142620
[TBL] [Abstract][Full Text] [Related]
4. A direct-to-patient telemedicine abortion service in Australia: Retrospective analysis of the first 18 months.
Hyland P; Raymond EG; Chong E
Aust N Z J Obstet Gynaecol; 2018 Jun; 58(3):335-340. PubMed ID: 29603139
[TBL] [Abstract][Full Text] [Related]
5. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days' gestation.
Hsia JK; Lohr PA; Taylor J; Creinin MD
Contraception; 2019 Sep; 100(3):178-181. PubMed ID: 31102629
[TBL] [Abstract][Full Text] [Related]
6. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days.
Schaff EA; Fielding SL; Eisinger SH; Stadalius LS; Fuller L
Contraception; 2000 Jan; 61(1):41-6. PubMed ID: 10745068
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Acceptability of Low-Dose Mifepristone and Self-Administered Misoprostol for Ultra-Early Medical Abortion: A Randomized Controlled Trial.
Li CL; Song LP; Tang SY; Zhou LJGY; He H; Mo XT; Liao YM
Reprod Sci; 2017 May; 24(5):731-737. PubMed ID: 27678099
[TBL] [Abstract][Full Text] [Related]
8. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
Louie KS; Tsereteli T; Chong E; Aliyeva F; Rzayeva G; Winikoff B
Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):457-64. PubMed ID: 25047120
[TBL] [Abstract][Full Text] [Related]
9. Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models.
Kerestes C; Murayama S; Tyson J; Natavio M; Seamon E; Raidoo S; Lacar L; Bowen E; Soon R; Platais I; Kaneshiro B; Stowers P
Contraception; 2021 Jul; 104(1):49-53. PubMed ID: 33789080
[TBL] [Abstract][Full Text] [Related]
10. Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation.
Boydell N; Reynolds-Wright JJ; Cameron ST; Harden J
BJOG; 2021 Oct; 128(11):1752-1761. PubMed ID: 34138505
[TBL] [Abstract][Full Text] [Related]
11. Client satisfaction and experience of telemedicine and home use of mifepristone and misoprostol for abortion up to 10 weeks' gestation at British Pregnancy Advisory Service: A cross-sectional evaluation.
Meurice ME; Whitehouse KC; Blaylock R; Chang JJ; Lohr PA
Contraception; 2021 Jul; 104(1):61-66. PubMed ID: 33974918
[TBL] [Abstract][Full Text] [Related]
12. Simplified medical abortion screening: a demonstration project.
Raymond EG; Tan YL; Comendant R; Sagaidac I; Hodorogea S; Grant M; Sanhueza P; Van Pratt E; Gillespie G; Boraas C; Weaver MA; Platais I; Bousieguez M; Winikoff B
Contraception; 2018 Apr; 97(4):292-296. PubMed ID: 29170088
[TBL] [Abstract][Full Text] [Related]
13. Could second-trimester medical abortion be offered as a day service? Assessing the feasibility of a 1-day outpatient procedure using pooled data from six clinical studies.
Shochet T; Dragoman M; Blum J; Abbas D; Louie K; Platais I; Tsereteli T; Winikoff B
Contraception; 2019 May; 99(5):288-292. PubMed ID: 30639446
[TBL] [Abstract][Full Text] [Related]
14. Telemedicine medical abortion service in Georgia: an evaluation of a strategy with reduced number of in-Clinic visits.
Tsereteli N; Mamatsashvili L; Tsertsvadze G; Tsereteli T; Platais I
Eur J Contracept Reprod Health Care; 2023 Apr; 28(2):141-146. PubMed ID: 36751958
[TBL] [Abstract][Full Text] [Related]
15. "It was close enough, but it wasn't close enough": A qualitative exploration of the impact of direct-to-patient telemedicine abortion on access to abortion care.
Kerestes C; Delafield R; Elia J; Chong E; Kaneshiro B; Soon R
Contraception; 2021 Jul; 104(1):67-72. PubMed ID: 33933421
[TBL] [Abstract][Full Text] [Related]
16. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
Schaff EA; Eisinger SH; Stadalius LS; Franks P; Gore BZ; Poppema S
Contraception; 1999 Jan; 59(1):1-6. PubMed ID: 10342079
[TBL] [Abstract][Full Text] [Related]
17. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial.
Schaff EA; Fielding SL; Westhoff C; Ellertson C; Eisinger SH; Stadalius LS; Fuller L
JAMA; 2000 Oct; 284(15):1948-53. PubMed ID: 11035891
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
Faucher P; Baunot N; Madelenat P
Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
[TBL] [Abstract][Full Text] [Related]
19. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
[TBL] [Abstract][Full Text] [Related]
20. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
